0001415889-23-008492.txt : 20230522 0001415889-23-008492.hdr.sgml : 20230522 20230522162012 ACCESSION NUMBER: 0001415889-23-008492 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230519 FILED AS OF DATE: 20230522 DATE AS OF CHANGE: 20230522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cole Douglas G. CENTRAL INDEX KEY: 0001486373 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39746 FILM NUMBER: 23944690 MAIL ADDRESS: STREET 1: AVEO PHARMACEUTICALS, INC. STREET 2: 75 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc. CENTRAL INDEX KEY: 0001821323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474005543 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-336-7540 MAIL ADDRESS: STREET 1: 100 BINNEY STREET STREET 2: STE 600 CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 form4-05222023_040501.xml X0407 4 2023-05-19 0001821323 Sigilon Therapeutics, Inc. SGTX 0001486373 Cole Douglas G. C/O SIGILON THERAPEUTICS, INC. 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 true false false false 0 Stock Option (Right to Buy) 0.6366 2023-05-19 4 A 0 8888 0 A 2033-05-18 Common Stock 8888 8888 D The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024 /s/ Matthew Kowalsky, Attorney-in-Fact 2023-05-22